Could MedTech find itself as the collateral damage if an RFK Jr. run HHS “goes wild” with FDA regulation of pharma and processed foods?
Because of the environmental and health risks that PFAS ─ per- and polyfluoroalkyl substances ─ pose, they are subject to a potential ban across the European Union. Such a ban would introduce a need for medical device manufacturers to identify and discontinue the sale of products containing PFAS, while also developing safe and effective alternatives. How will suppliers across the EU approach the impending shift away from these “forever chemicals”?
Health equity can provide equal opportunity for patients to achieve the best care possible. Medtech leaders from Boston Scientific, Sequel Med Tech, and ZEISS Medical Technology share how healthcare delivery, data transparency, and industry collaboration can provide more value to patients.
Congress must decide the future of the Acute Hospital Care at Home (AHCAH) program, an initiative of the Centers for Medicare & Medicaid Services (CMS) that, without legislative action, will expire on December 31, 2024. To ensure beneficiaries can receive various levels of care in their preferred settings, this brief provides immediate–term federal policy reform recommendations for the potential reauthorization of the AHCAH model while outlining key issues for policymakers to consider when further research and data emerge.
Q2/24 Life Science and Health Care Law Updates by Hogan Lovells including key trends in the EU and Big Five (France, Germany, Italy, Spain, UK) regulatory, corporate, compliance, competition, and privacy.
Law firm, Hogan Lovells, analyzes the changes to the updated enforcement policy and provide key takeaways for entities responsible for communication regarding approved/cleared medical products.
The EU Data Act will be applicable from September 12, 2025. Given the consequent steps that will be required to comply with the EU Data Act, medical and health devices’ companies would do well to already commence assessing what they will need to do to comply with it.
Information polarization affects public opinion. It can also affect investors. As we approach upcoming elections in different countries, it is crucial to understand how these political events could significantly reshape the landscape for MedTech investments. This article outlines an approach to help investors navigate and understand the interplay of political climates, cultural norms, and healthcare policies without getting emotionally attached to them. It emphasizes the importance of open dialogue, diversity, critical thinking, and cross-cultural collaborations to determine the true potential of MedTech innovations.
